{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Supplementary Table 1"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Supplementary Table 1","index":0,"n_rows":38,"n_cols":5,"rows_kept":38,"merged":[[0,0,0,4],[1,4,2,4],[37,0,37,4]],"flags":["formulas_cached_only"]}
["Supplementary Table 1 | Demographics and clinicopathologic characteristics of LARC patients with PNI(+) of FJCH."]
[null,null,"S+CT ","S+CRT","P-value"]
[null,null,"(N=83)"," (N=15)"]
[null,"Age"]
[null,"≤65","71 (85.5%)","13 (86.7%)",1]
[null,">65","12 (14.5%)","2 (13.3%)"]
[null,"Sex"]
[null,"Male","50 (60.2%)","10 (66.7%)",0.855]
[null,"Female","33 (39.8%)","5 (33.3%)"]
[null,"CEA"]
[null,"Normal/Borderline","39 (47.0%)","4 (26.7%)",0.152]
[null,"Elevated","28 (33.7%)","9 (60.0%)"]
[null,"Unknow","16 (19.3%)","2 (13.3%)"]
[null,"Tumor size"]
[null,"≤ 3cm","15 (18. 1%)","2 ( 13.3%)",0.0697]
[null,"3-5cm","52 (62.7%)","6 (40.0%)"]
[null,"> 5cm","16 (19.3%)","7 (46.7%)"]
[null,"Tumor differentiation"]
[null,"Grade I/II","69 (83.1%)","10 (66.7%)",0.259]
[null,"Grade III/IV","14 (16.9%)","5 (33.3%)"]
[null,"TD"]
[null,"Negative","56 (67.5%)","9 (60.0%)",0.79]
[null,"Positive","27 (32.5%)","6 (40.0%)"]
[null,"Stage"]
[null,"II","9 (10.8%)","2 (13.3%)",1]
[null,"III","74 (89.2%)","13 (86.7%)"]
[null,"T Stage"]
[null,"T1-2","6 (7.2%)","0 (0%)",0.529]
[null,"T3","69 (83.1%)","13 (86.7%)"]
[null,"T4","8 (9.6%)","2 (13.3%)"]
[null,"N Stage"]
[null,"N0","9 (10.8%)","2 (13.3%)",0.914]
[null,"N1","42 (50.6%)","8 (53.3%)"]
[null,"N2","32 (38.6%)","5 (33.3%)"]
[null,"Number of LND"]
[null,"<12","9 (10.8%)","2 (13.3%)",1]
[null,"≥12","74 (89.2%)","13 (86.7%)"]
["LARC, locally advanced rectal cancer; FJCH, Fujian Cancer Hospital; S,surgery; CRT, chemoradiotherapy; CT,chemotherapy; PNI, perineural invasion; CEA, carcinoembryonic antigen; TD, tumor deposits; LND, dissected lymph nodes.  "]